Replies to post #1826 on Insmed Inc (INSM)

[rfoable1]

All longs,
Isn't it sweet to see "the inevitable" success of the INSM science & commercialization blossom, and the bashers just scratch their heads and panic over their positions in bewilderment?

This is early in the game. By the time of the INSM 3rd quarter financial report - sometime in October and after the date (Sept 27) the judge in the TRCA lawsuit stated she would issue her Markman hearing patent claims guidance - things are really going to warm up.

AIDS lipodystrophy, severe insulin resistance, myotonic dystrophy, hip fracture, burns, off-label for Noonan's, etc. etc.

PhII IGFBP3 results next year as an adjunct to cancer treatments.

$3-$4 by year end is likely - and that's possibly a low estimate. Wow.

Love the INSM science and the calm progress of INSM's program.
Cheers

[rfoable1]

All longs,
Isn't it sweet to see "the inevitable" success of the INSM science & commercialization blossom, and the bashers just scratch their heads and panic over their positions in bewilderment?

This is early in the game. By the time of the INSM 3rd quarter financial report - sometime in October and after the date (Sept 27) the judge in the TRCA lawsuit stated she would issue her Markman hearing patent claims guidance - things are really going to warm up.

AIDS lipodystrophy, severe insulin resistance, myotonic dystrophy, hip fracture, burns, off-label for Noonan's, etc. etc.

PhII IGFBP3 results next year as an adjunct to cancer treatments.

$3-$4 by year end is likely - and that's possibly a low estimate. Wow.

Love the INSM science and the calm progress of INSM's program.
Cheers